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To assess the adequacy of a routine screening to identify cervical intraepithelial neoplasia 2 or worse (CIN2þ) in women over 50
years of age, a retrospective cohort was set in six Italian organised population-based screening programmes. In all, 287330 women
(1714550 person-years of observation, 1110 cases) screened at age 25–64, with at least two cytological screening tests, the first
negative, were followed from their first negative smear until a biopsy proven CIN2þ lesion or their last negative smear. For women
aged 25–49 and 50–64 years, crude and age-standardised detection rate (DR), cumulative risk (CR), adjusted hazard risk for number
of previous negative screens, probability of false-positive CIN2þ after two or more smear tests were calculated. Detection rate is
significantly lower over 50 years of age. Multivariable analysis shows a significant protective effect from four screening episodes
(DR¼0.70, 95% CI: 0.51–0.97); the effect of age X50 is 0.29 (95% CI: 0.24–0.35). The CR of CIN2þ is at least eightfold higher in
women o50 (CR¼2.06, 95% CI: 1.88–2.23) after one previous negative test than in women X50 years with four screens
(CR¼0.23, 95% CI: 0.00–0.46). Over 50 years of age, after four tests at least three false-positive cases are diagnosed for every true
positive. Benefits arising from cytological screening is uncertain in well-screened older women.
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European recommendations state that cervical cancer screening
should start at the latest at 30 years and stop not before 60 years of
age. Screening intervals should be between 3 and 5 years (Coleman
et al, 1993).
International Agency for Research on Cancer recommendations
for cervical cancer screening suggest 5-yearly screening over 50
years of age; 3-yearly screening is recommended at age 25–49
years in countries with the necessary resources (International
Agency for Research on Cancer, 2005).
The overtreatment is intrinsic in cervical cancer screening: for
preventing one invasive cancer, seven to eight preinvasive lesions
should be treated (Ponten et al, 1995).
Considering invasive cervical cancer, several studies (Interna-
tional Agency for Research on Cancer, 1986; Gustafsson et al, 1995;
Cruickshank et al, 1997; Coldman et al, 2005; Ronco et al, 2005)
show a trend of decreasing risk with increasing number of smear
tests.
Detection rates (DRs) for cervical intraepithelial neoplasia (CIN)
fall with increasing age (Gustafsson et al, 1995; Gram et al, 1998)
and number of previous smears (Gram et al, 1998).
The low risk level in well-screened women after 50 years of age
might not justify the costs and harms associated with screening,
such as overdiagnosis, anxiety, unnecessary treatment and
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sreduction in quality of life associated with false-positive results
(International Agency for Research on Cancer, 2005). On the basis
of age and screening history, a subset of women could be
identified, for whom the risk of preinvasive and invasive lesions is
negligible and screening might be safely stopped before the
currently recommended age limit (Sherlaw-Johnson et al, 1999) or
different screening intervals might be adopted at different ages
(International Agency for Research on Cancer, 2005).
The balance between the risk of being diagnosed with a
preinvasive or invasive lesion and that of getting a false-positive
cytohistological report must be discussed considering ethic and
practical implications.
Objective of the present study is to estimate the DR and the
cumulative risk (CR) of CIN2 or more severe lesions (CIN2þ) and
to compare it with the probability of false-positive episodes in
women o50 or X50 years of age, with at least two cytological
screening tests, the first negative, as observed in six Italian
organised population-based screening programmes.
MATERIALS AND METHODS
Study design
The study is based on a retrospective cohort of women screened at
age 25–64 years, who had at least two cytological screening tests
on 31 December 2000, the first being reported as negative. Women
were recruited from six Italian organised population-based
screening programmes (Ferrara, Florence, Mantova, Ravenna,
Turin and Viterbo): women aged 25–64 years are invited every 3
years by mail; monitoring system and quality assurance have been
established according to the European guidelines.
Women were followed from the date of their first negative smear
test available in the archives until a biopsy proven CIN2þ lesion
was diagnosed or until their last negative smear result (performed
within 31 December 2000). We considered as a negative smear test
all the smears either with a negative cytology or with a positive
cytology followed by a negative biopsy proven CIN2þ diagnosis
performed within 300 days from the smear test, as women are
readmitted to routine screening. Follow-up continued for women
with a less severe than CIN2þ histological diagnosis. The
histological diagnosis was issued within 30 September 2001
following a smear test performed within 31 December 2000.
As different cytological classifications were used in screening
centres, data were standardised according to a common
cytological and histological classification (Bethesda NCI Work-
shop, 1993).
Negative smear tests performed within 300 days of the oldest
available test for clinical or technical reasons were assumed as a
unique screening episode, as recommended in screening protocols
of the programmes that supplied data. To count the previous
negative screening episodes, we individuated an index test for each
woman. In a screening setting, the index test activates further
assessments to ascertain the occurrence of the studied lesion; so we
did not count it among the negative ones and we used it to define
the time of exit from the cohort. For negative women, the last
available negative smear was considered as the index test.
However, for the cases, four different situations occurred: (1) the
index test was the most recent smear performed within 300 days
since the CIN2þ histological report, (2) when two or more tests
were performed within 300 days of the positive histological result,
the one with the worst diagnosis was chosen, (3) if the last
smear test was performed at more than 300 days from the
histological diagnosis, this test was identified as the index if
positive, (4) again, if the last smear test was performed at more
than 300 days before the histological diagnosis but was negative,
the date of the histological diagnosis was considered as the date of
the index test.
Statistical analysis
Persons-years were computed from the date of the oldest negative
smear test available in the screening history. For negative women,
the index test was assumed as the end point of the observation
period whereas for cases, the end point was the midpoint between
the index test and the last available negative smear test, as we
assumed that the lesion occurred on average in the midpoint of the
interval between two tests.
Person-years were calculated according to time-dependent
variables: the number of previous negative screening episodes
(five categories: 1, 2, 3, 4 and 5þ) and 5-year age groups.
Crude and age-standardised (direct method) CIN2þ DR was
calculated as cases on person-years, CR, applying the exponential
formula, and their confidence intervals at 95% (95% CI) were
calculated for women of 25–49 and 50–64 years of age. It must be
noted that the age intervals used to calculate the CR have different
lengths. A Score test for trend of DRs by age class was computed
(StataCorp, 2005).
For women with two or more smear tests, we estimated the joint
probability of a false-positive CIN2þ diagnosis, when both
cytology and the histology are false positive. We used the formula:
pðFPÞ¼1  f 1  ½ ð 1   VcytÞ ð 1   VhisÞ g
s
where Vcyt and Vhis are the specificities of cytological and
histological diagnosis and s is the number of screening episodes.
We assumed the following combinations of cytological and
histological specificities, respectively: 0.97–0.94, 0.96–0.95,
0.95–0.96 and 0.94–0.97 to calculate the number of false positives
(FP). We estimated the probability of true-positive results (TP) as
the probability of positive results (the CR per 10000) minus the
number of FP. The specificity values used are more favourable
than the range of cytological and histological specificity shown in
literature for HSIL/CIN2þ (Nanda et al, 2000; Stoler and
Schiffman, 2001), and they represent the minimum values that
combined together allow to estimate the TP number. We estimated
the ratio between TP and FP, and the ratio between CR and FP.
The effect of multiple factors on the risk of CIN2þ was
modelled using Cox regression for left-truncated and right-
censored data. We have considered five categories of the number
of previous negative screens and age o50 or X50 years as time-
dependent variables, whereas the interval between the index test
and the last negative smear has been considered as a fixed variable.
Calendar time was used as time axis. We calculated P-values for
trend for the number of previous negative screens as an ordinal
variable. P-values less then 0.05 were considered statistically
significant.
Data were analysed through SAS (SAS Institute Inc., USA, 1999–2001)
and STATA (StataCorp, 2005) softwares.
RESULTS
Screening data were available from the six programmes. Screening
episodes, as defined in the Material and methods section, were
569713. The study included 287330 women for a total of 1714550
person-years of observation and 1110 CIN2þ cases.
Distribution of the study population and DR (95% CI) by
screening programmes is described in Table 1.
Cervical intraepithelial neoplasia 2þ DR (Table 2, Figure 1) was
most frequent among 25- to 29-year-old women (DR¼14.11, 95%
CI: 12.30–16.18 per 10000 person-years), and a statistically
significant decreasing trend (Score test for trend of rates:
P-valueo0.0001) was observed with increasing age, the lowest
DR being observed in the 50–54 (DR¼2.28, 95% CI: 1.76–2.96)
and in the 60–64 (DR¼2.43, 95% CI: 1.85–3.19) age groups.
Detection rate is rather stable (around 2 per 10000 person-years)
and significantly lower over 50 years of age.
Adequacy of cervical screening in older women
P Armaroli et al
240
British Journal of Cancer (2008) 99(2), 239–244 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sWhen comparing 25–49 vs 50–64 age groups (Table 3), DR was
constantly lower in the latter in all subgroups defined according to
the number of previous negative screens. A small, statistically not
significant, protective effect was observed in women above 50
years of age with more than one previous negative smear test
(Score test for trend of rates: P-value40.005).
Multivariable analysis when adjusting for screening programme,
age o50 or X50 years and interval between index and last
negative smear demonstrate a statistically significant protective
effect of four or more previous negative tests, but the effect of age
X50 years was much stronger (Table 4).
When comparing women o50 years of age with one previous
negative test, the CR of CIN2þ (Table 5) is at least fivefold higher
than in older women with one test, and raising to about eight if
comparing younger women with one screen to women of age X50
years with four tests.
When considering a cytological specificity of 0.97 and a
histological specificity of 0.94 or the opposite combination, the
cumulative probability of an FP CIN2þ is about 90, resulting
as a sum of FP in each screening episode (Table 6). The ratio
between TP and FP diagnosis is about 1 for women above 50 years
of age who underwent one, two or three screening episodes,
and it even reaches the value of 0.28 and 0.29 after four or five
episodes, respectively (Table 6). However, in younger women this
ratio is constantly above 10.44. The situation is similar when
considering a cytological specificity of 0.96 and a histological
specificity of 0.95 or its opposite combination. Actually, in this
case, the cumulative probability of an FP CIN2þ is about 100;
the ratio between TP and FP in women below 50 years of age
ranges from 9.30 to 14.34 (i.e., it is lower than with the other
combination) but in women above 50 years of age, the ratio is
always below 1 and it reaches the value of 0.16 after four or more
screening episodes.
DISCUSSION
In women X50 years of age, the CR of CIN2þ is significantly
lower compared to younger women, irrespective of the number of
previous negative screening episodes. Combining the effect of age
and the effect of the number of previous negative smears in the
case of a CIN2þ diagnosis every 1 true-positive CIN2þ we may
expect between 1 and 6.3 false-positive cases in the worst scenario,
according to the combination in Table 6.
The present study is based on a large multicentric cohort and a
great amount of person-years; nevertheless a number of points in
the study design need to be discussed.
Ideally, the protective effect of cervical screening should be
estimated on the risk of invasive carcinoma. Nevertheless, we
chose CIN2þ as the outcome because in the whole cohort (287330
women, 1110 CIN2þ cases), we found few invasive carcinomas
(n¼61) only. Incidence of cervical cancer in the study population
is not comparable to that of the general population as women are
selected for having performed at least two cytological screening
tests, the first negative. Moreover, screening protocol addresses
women with CIN2þ diagnosis to treatment.
Usually DR is calculated per smear as it is used to estimate a
lesion prevalence, whereas here it was calculated as cases on
Table 1 Distribution of the study population and DR (with 95% CI) by screening programme
Screening programme Starting year No. of women (%) Person-years No. of cases DR (95% CI)
Firenze 1986 162314 (56) 1273442 824 6.47 (6.04–6.93)
Torino 1992 54367 (19) 225546 69 3.06 (2.42–3.87)
Mantova 1993 23571 (8) 92632 79 8.53 (6.84–10.63)
Ravenna 1995 19476 (7) 55933 57 10.19 (7.86–13.21)
Ferrara 1996 22181 (8) 52011 80 15.38 (12.36–19.15)
Viterbo 1997 5421 (2) 14986 1 0.67 (0.09–4.74)
Total — 287330 1714550 1110
CI¼confidence interval; DR¼detection rate.
Table 2 Detection rate (per 10
 4 person-years) of CIN2+ by age class
Age class (years) No. of cases (N¼1110) Person-years (N¼1714550) DR (95% CI) (per 10
 4 person-years)
25–29 205 145296 14.11 (12.30–16.18)
30–34 252 229902 10.96 (9.69–12.40)
35–39 217 245243 8.85 (7.75–10.11)
40–44 192 259391 7.40 (6.43–8.53)
45–49 111 265922 4.17 (3.47–5.03)
50–54 57 249725 2.28 (1.76–2.96)
55–59 52 213905 2.43 (1.85–3.19)
60–64 24 105166 2.28 (1.53–3.41)
CI¼confidence interval; CIN¼cervical intraepithelial neoplasia; DR¼detection rate. Score test for trend of rates: P-valueo0.0001.
DR by age group
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Figure 1 Detection rate (per 10
 4 person-years) of CIN2þ by age
class.
Adequacy of cervical screening in older women
P Armaroli et al
241
British Journal of Cancer (2008) 99(2), 239–244 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sperson-years to take into account the screening history and the
effect of previous tests on diagnosis.
We stratified the cohort choosing 50 years of age as cutoff. Even
though the age groups have different lengths (25 and 15 years), this
choice was based on previous studies showing a strong risk
reduction for CIN2þ after 50 years of age (Gustafsson et al, 1995;
Gram et al, 1998; International Agency for Research on Cancer,
2005). Also, our results show that DR of CIN2þ decreases
significantly from 4.17 in the 45–49 age group to about 2 after 50
years of age (Table 2). When stratifying for 5-years age classes and
previous screening episodes, after two, the DR before 50 years is
doubled compared to older women (data not shown). To verify
that the use of two groups of 25 and 15 years length would not
affect our study conclusions, we estimated CR using 25–44 and
45–64 age groups, and the results show that the risk in younger
women is at least threefold higher than that in older ones (the ratio
ranging from 3.3 to 6.3).
As shown in Table 6, one critical point in cervical screening is
the specificity of cytohistological diagnosis.
We estimated the joint probability of a false-positive CIN2þ
diagnosis within a screening episode, as it depends on the
probability of being a false-positive case at both the primary and
the assessment test, for the adopted diagnostic category.
Several meta-analyses (Fahey et al, 1995; Nanda et al, 2000) have
shown that cytological specificity ranges from 14 to 97% (Fahey
et al, 1995). We assumed a specificity ranging from 0.94 to 0.97,
according to estimates from studies on low-risk screening
attenders (Nanda et al, 2000). Lower values did not allow the
estimation of the true positives; anyway, it is very unlikely that a
specificity as low as 0.60–0.70 might occur in a modern cytological
screening setting (International Agency for Research on Cancer,
2005).
Histological diagnosis reproducibility might be as questionable
as cytological diagnosis. Studies of cervical biopsies have shown
fair-to-poor interobserver and intraobserver agreement in report-
ing (Robertson et al, 1989). We assumed histological specificity to
be at least 0.94 according to the findings of ASCUS-LSIL Triage
study (Stoler and Schiffman, 2001), which reviewed 2237 original
histological slides.
According to these assumptions, the ratio between true-positive
and false-positive results is almost above 10 under 50 years of age,
whereas among older women, for each real case identified, one
false positive is also diagnosed. After four tests, at least three false-
positive cases are diagnosed every true positive (Table 6). These
considerations hold also in the case of two 20-year age groups, that
is 25–44 and 45–64 (data not shown). Yet, in our results, the effect
is even stronger, thus demonstrating that the screening benefits
over 50 years is uncertain.
Table 3 Detection rate (per 10
 4 person-years) of CIN2+ by number of previous screening episodes
Age class
(years)
No. of previous
screening
episodes
No. of cases
(N¼1110)
Person-years
(N¼1714550)
DR (95% CI)
(per 10
 4
person-years)
DR ratio
(95% CI)
All ages 1 594 933165 5.98 (5.49–6.47) 1
2 300 420778 7.19 (6.37–8.01) 1.12 (0.98–1.29)
3 131 197909 7.58 (6.04–9.12) 1.04 (0.86–1.26)
4 46 92676 7.43 (3.29–11.58) 0.78 (0.58–1.05)
5+ 39 70022 6.32 (4.04–8.60) 0.87 (0.63–1.21)
25–49 1 518 634520 8.16 (7.49–8.90) 1
2 268 280039 9.57 (8.49–10.79) 1.17 (1.01–1.36)
3 114 129361 8.81 (7.34–10.59) 1.08 (0.88–1.32)
4 41 58929 6.96 (5.12–9.45) 0.85 (0.62–1.17)
5+ 36 42905 8.39 (6.05–11.63) 1.03 (0.73–1.44)
50–64 s 1 76 298645 2.55 (2.03–3.19) 1
2 32 140738 2.27 (1.61–3.22) 0.89 (0.59–1.35)
3 17 68548 2.48 (1.54–3.99) 0.98 (0.58–1.65)
4 5 33747 1.48 (0.62–3.56) 0.58 (0.24–1.44)
5+ 3 27117 1.11 (0.36–3.43) 0.44 (0.14–1.38)
CI¼confidence interval; CIN¼cervical intraepithelial neoplasia; DR¼detection rate. Standardised and stratified by age (25–49 years, 50–64 years). Score test for trend of
rates: P-value40.5.
Table 4 Relative risk (hazard ratios) of CIN2+ and 95% CI, adjusted for
screening programme and interval between index and last screening
episode
Factors Level
Relative risk
(95% CI)
No. of previous screening episodes 1 (referent) 1
2 1.10 (0.95–1.28)
3 0.96 (0.78–1.19)
4 0.70 (0.51–0.97)
5 0.65 (0.45–0.92)
Age 25–49 years (referent) 1
50–64 years 0.29 (0.24–0.35)
CI¼confidence interval; CIN¼cervical intraepithelial neoplasia. Test for trend on
risks referring to n screening episodes: P-value40.5.
Table 5 Cumulative risk (per 100) between 25 and 49 years and 50 and
64 years of CIN2+
Cumulative risk (per 100) (95% CI)
No. of previous negative
screening episodes 25–49 years 50–64 years
1 2.06 (1.88–2.23) 0.36 (0.28–0.45)
2 2.46 (2.15–2.78) 0.38 (0.24–0.52)
3 2.74 (2.01–3.47) 0.36 (0.17–0.54)
4 3.05 (0.74–5.30) 0.23 (0.00–0.46)
5+ 2.06 (1.26–2.85) 0.23 (0.00–0.52)
CI¼confidence interval; CIN¼cervical intraepithelial neoplasia.
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ment and its complications, adverse effects of treatment,
unnecessary treatment, adverse effects of labelling or early
diagnosis, anxiety and costs generated by investigations and
treatment (International Agency for Research on Cancer, 2005).
Hence an effort to increase specificity is needed, especially in older
age groups.
A different CIN2þ DR is reported among the participating
centres, likely due to real incidence differences and not due to
diagnostic variability among laboratories. Actually, data on
reproducibility that are available for cytological diagnosis in Italy
showed that agreement was generally good (Montanari et al, 2003).
As the cohort includes women coming from six different Italian
screening programmes, with different periods of observation, the
CIN2þ DRs must be taken with caution. For this reason, we have
performed an analysis on the Florence and Turin data only, as they
contribute for 75% of the observed women. The estimates of the
DRs, ratios and trends are very similar to those calculated on the
whole cohort.
Centres with the highest CIN2þ incidence (Ravenna, Ferrara
and Mantova) gave a limited contribution to the cohort as to
person-years but they provided a great number of cases; this could
have reduced the stronger effect observed in a previous analysis
(Armaroli et al, 2005). Thus, decision makers should take into
account the local CIN2þ prevalence when implementing local
intervention strategies, as in single areas, the probability of being a
case might be higher than that of being a false positive.
Women who undergo screening more frequently may have a
lower risk of cervical disease because of a healthier lifestyle and a
better access to treatment (Ronco et al, 1991). In the present study,
DRs are low also because women were selected as having had at
least one negative smear before the index test. Moreover, survival
within the cohort is subordinated to not having shown a previous
high-grade cervical lesion, as follow-up is stopped when a CIN2þ
lesion occurs, that is the probability of being positive to the last Pap
smear is conditional to having accumulated previous negative test.
Detection rates are affected by the duration of sojourn time and
by the proportion of lesions that regress. Moreover, the sensitivity
of smear test for long-sojourn time lesions as CIN2 (International
Agency for Research on Cancer, 1986) depends on the number of
smear tests performed during the sojourn time; on the other hand,
frequent testing increases the DR of those significant lesions. This
last effect may explain the observed risk reduction when the
number of screening episodes increases, particularly after four
negative tests.
The results of the present study are in agreement with other
studies showing a risk reduction with increasing age (Cruickshank
et al, 1997; Sasieni et al, 2003; Coldman et al, 2005) and the
number of previous negative smear tests (Coldman et al, 2005).
Few cases of preinvasive lesions were diagnosed ex novo in well-
screened women aged over 50 years (two or more 3- to 5-yearly
negative screens) (Van Wijngaarden and Duncan, 1993) or in
women with three consecutive (at most 3-yearly) negative screens
before 50 years age (Cruickshank et al, 1997) or in women with at
least three negative smear tests screens between 41 and 49 years of
age (Gustafsson et al, 1995).
Considering invasive cervical cancer, a trend of decreasing risk
with increasing number of smear tests is reported (International
Agency for Research on Cancer, 1986; Gustafsson et al, 1995;
Coldman et al, 2005).
In Turin (Italy), invasive carcinoma incidence during 1992–
1998 was reduced by 75% in women who attended one screening at
least, as compared to nonattenders (3.0 vs 9.5/100000 person-
years), the latter showing the highest incidence (Ronco et al, 2005).
The results of the present study, in accordance with other reports,
may suggest that the adequacy of a routine screening test to identify
early lesions in women over 50 years of age with at least four
previous negative screens is questionable; possible alternative
strategies may be explored. Women might be involved in the
decision whether to stop screening or to undergo just another smear
test in their life after evaluating the individual risk of a CIN2þ at
further screening through algorithms based on age, screening
history and living area-specific DRs. Comparing the future
individual risk of being a case or a false positive may support and
strengthen individual choices. The decision of stopping screening
may also be supported by a negative result of HPV testing.
Informing women about the risk related to changes in their and
their partners’ sexual habits (Brisson et al, 1994) may allow
spontaneous return to the usual screening protocols.
Such strategies agree with the IARC recommendations for
implementation on cervical cancer screening (International
Agency for Research on Cancer, 2005) and with the IARC Working
Group statement that there is little benefit from screening old
women who have always tested negative in an organised screening
programme. In particular, for women over 50 years of age, the
Working Group recommend a 5-year screening interval.
The results of our study support the opinion that the benefit
arising from cytological screening is uncertain in older women.
Ethical and practical considerations subsequent to screening
intensity reduction must be taken into account. A possible
Table 6 Cumulative risk (CR), probabilities of cytological and histological false-positive diagnosis and of true positive per 10000, ratio between true-
positive and false-positive, ratio between CR and false-positive, by screening episodes, for different combination of cytological and histological specificities
CR (per 10000)
True positive
(per 10000) True positive/false positive
Positive/false
positive
No. of screening
episodes
25–49
(years)
50–64
(years)
False positive
(per 10000)
25–49
(years)
50–64
(years)
25–49
(years)
50–64
(years)
25–49
(years)
50–64
(years)
Cytological specificity: 0.97, histological specificity: 0.94 or cytological specificity: 0.94, histological specificity: 0.97
1 206 36 18.00 188.00 18.00 10.44 1 11.44 2
2 246 38 17.97 228.03 20.03 12.69 1.11 13.69 2.11
3 274 36 17.94 256.06 18.06 14.28 1.01 15.28 2.01
4 305 23 17.90 287.10 5.10 16.04 0.28 17.04 1.28
5 206 23 17.87 188.13 5.13 10.53 0.29 11.53 1.29
Cytological specificity: 0.96, histological specificity: 0.95 or cytological specificity: 0.95, histological specificity: 0.96
1 206 36 20.00 186.00 16.00 9.30 0.80 10.30 1.80
2 246 38 19.96 226.04 18.04 11.32 0.90 12.32 1.90
3 274 36 19.92 254.08 16.08 12.75 0.81 13.75 1.81
4 305 23 19.88 285.12 3.12 14.34 0.16 15.34 1.16
5 206 23 19.84 186.16 3.16 9.38 0.16 10.38 1.16
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sconsequence might be an increase in invasive lesion incidence,
compared to a major resource saving. Estimates of unprevented
cervical cancers are in the magnitude of about two cases per
100000 person-years (Sherlaw-Johnson et al, 1999). It is thus
desirable to evaluate if benefits arising from saved resource
allocation to more cost-effective interventions would make
acceptable to reduce or to stop screening in 50-year-old or older
women with a negative documented screening history.
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